תחזית צמיחת רווח נקי למניה לשנה הבאה Cardiff Oncology Corp (CRDF)

High patent barriers and R&D costs limit entry into the targeted therapy niche. Cardiff Oncology, Inc. (CRDF) is developing onvansertib, whose compatibility with standards of care promises sustainable margins. However, the lack of commercial products leaves the company dependent on investment. The consensus estimate for net profit growth rates reflects current dynamics, where the actual value is -10.20.
פילוחי נתונים אנליטיים מרוכזים עבור Cardiff Oncology, Inc. (CRDF)

The investment attractiveness of Cardiff Oncology, Inc. (CRDF) is based on the success of its biotechnological developments. This metric calculates the percentage change in expected earnings per share, reflecting the analysts' consensus forecast for future profitability. The one-year forward EPS growth trend allows for an assessment of the impact of geopolitical risks and regulatory barriers on the pace of drug commercialization. A stable trend in this indicator confirms the company's fundamental resilience to external shocks.